The invention relates to CD34- stem cells for use as a medicament in the treatment of a subject afflicted with a gastrointestinal disorder. The invention relates to genetically modified CD34- stem cells, wherein each of the genetically modified CD34- stem cells contains an exogenous nucleic acid comprising (i) a region encoding a protein which enhances endothelial cell growth, which region is operably linked to (ii) an endothelium-specific promoter or promoter/enhancer combination, and CD34- stem cells without genetic modification. In a preferred embodiment of the invention the cells and medical use thereof are characterised in that the introduction of the CD34-stem cells is not preceded, accompanied or followed by myeloablation.
